BOT only launched in Feb this year. MSB have a similar structure to BOT in that they supply their product for free to those who can’t pay, the difference appears to be BOT has told the market the size of this component while MSB hasn’t.
It is hard to compare sales numbers between BOT and MSB as MSB has included sales to their distributor in the composite sales figure. I do wonder what the market would have made of BOT if they had only provided a single sales number constructed of the number of scripts written for Sofdra multiplied by the list price per script.
To answer your question I can’t answer as the information I need to make a reasoned response appears to have not been released by MSB (i.e. number of patients treated, number of vials used per patient, and net revenue per patient). I certainly hope that this is the beginning of a massive upswing in sales for MSB as the Australian biotech sector needs every success it can get - investors won’t support the sector unless there are some massive successes as the failure rate is so inherently high in biotech. I want to see every Australian biotech succeed.
MSB Price at posting:
$2.41 Sentiment: None Disclosure: Not Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)